Breast CarePub Date : 2023-06-01DOI: 10.1159/000530620
L. Kiesel
{"title":"Effects and Risks of Hormonal Therapy before and after BC Therapy","authors":"L. Kiesel","doi":"10.1159/000530620","DOIUrl":"https://doi.org/10.1159/000530620","url":null,"abstract":"Hormones are the main regulators of the development and function of the normal breast and relevant for several treatment modalities in many women with breast cancer. Studies on exogenously added steroids and their effects on the breast in menopausal women have resulted in a global change in the perception of many aspects of this topic. Especially, the publication of data on breast cancer risk related to hormone therapy has caused a lot of anxiety in women.","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"18 1","pages":"157 - 157"},"PeriodicalIF":2.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47336536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2023-02-01DOI: 10.1159/000529757
B. Gulluoglu, S. Corradini
{"title":"Front & Back Matter","authors":"B. Gulluoglu, S. Corradini","doi":"10.1159/000529757","DOIUrl":"https://doi.org/10.1159/000529757","url":null,"abstract":"","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43274087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2022-12-01DOI: 10.1159/000528398
B. Gulluoglu
{"title":"Contents Vol. 17, 2022","authors":"B. Gulluoglu","doi":"10.1159/000528398","DOIUrl":"https://doi.org/10.1159/000528398","url":null,"abstract":"Marija Balic, MD – Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria Heba Gamal El Din Mohamed Mahmoud, MD – Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt Theodoros Foukakis, MD – Department of Oncology, Karolinska Institutet and University Hospital, Stockholm, Sweden Alessandra Gennari – Division of Oncology, Maggiore della Carità Hospital, Novara, Italy Bahadir M. Gulluoglu, MD – Department of General Surgery, Marmara University School of Medicine, Istanbul, Turkey Thomas Helbich, MD – Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria Wolfgang Janni, MD – Department of Obstetrics and Gynecology, University Hospital Ulm, Ulm, Germany Eva Johanna Kantelhardt, MD – Department of Gynecology, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany Marion Kiechle, MD – Department of Obstetrics and Gynecology, Technical University Munich, Munich, Germany Ludwig Kiesel, MD – Department of Gynecology and Obstetrics, University Hospital Münster, Münster, Germany Sibylle Loibl, MD – German Breast Group, Neu-Isenburg, Germany Martina Mittlböck, PhD – Center for Medical Statistics, Informatics, and Intelligent Systems, Section for Clinical Biometrics, Medical University of Vienna, Vienna, Austria Shani Paluch-Shimon, MD – Breast Oncology Unit, Department of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel Angelo Paradiso, MD – Experimental Medical Oncology, Istituto Tumori G. Paolo II, IRCCS, National Cancer Institute, Bari, Italy Cristina Saura, MD – Breast Cancer Unit, Medical Oncology Service, Vall d’Hebron University Hospital, Barcelona, Spain Hans-Jörg Senn, MD – Tumor and Breast Center ZeTuP, St. Gallen, Switzerland Günther Steger, MD – Clinical Division of Oncology, Department of Medicine I, Comprehensive Cancer Center of the Medical University of Vienna, Vienna, Austria Janice Tsang, MD – Medical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Michael Untch, MD – Department of Gynecology, HELIOS Hospital Berlin Buch, Berlin, Germany","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"17 1","pages":"I - VIII"},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46090301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2022-12-01DOI: 10.1159/000528381
{"title":"PharmaNews","authors":"","doi":"10.1159/000528381","DOIUrl":"https://doi.org/10.1159/000528381","url":null,"abstract":"Ab sofort ist der Poly(ADP-Ribose)-Polymerase (PARP)-Inhibitor Niraparib auch als Filmtablette verfügbar. Niraparib ist damit für eine Übergangsfrist bis voraussichtlich Ende des Jahres sowohl als Filmtablette als auch als Hartkapsel erhältlich für die Monotherapie erwachsener Patientinnen mit fortgeschrittenem epithelialem (FIGO-Stadien III und IV) hochgradigem Karzinom der Ovarien, der Tuben oder mit primärem Peritonealkarzinom, die nach einer Platin-basierten Erstlinien-Chemotherapie ein Ansprechen (komplett oder partiell) haben, sowie für die Monotherapie erwachsener Patientinnen mit Rezidiv eines Platin-sensiblen, hochgradigen serösen epithelialen Karzinoms der Ovarien, der Tuben oder mit primärem Peritonealkarzinom, die sich nach einer Platin-basierten Chemotherapie in Remission (komplett oder partiell) befinden [1, 2]. Die neue Tablettenformulierung ist bioäquivalent mit der bisher verfügbaren Hartkapsel und enthält die gleiche Wirkstoffmenge; Behandlungsschema, Wirksamkeit und Sicherheitsprofil sind unverändert [1, 2]. Die Niraparib Filmtablette ist kleiner als die Hartkapsel, beinhaltet keine Gelatine, weniger Laktose und keinen Farbstoff E102 [1, 2]. Die Tablettenformulierung ist seit 01.10.2022 in der Lauer-Taxe gelistet und wird die Hartkapsel als Darreichungsform ablösen.","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"17 1","pages":"595 - 598"},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41451873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
